ITGAM and B-cell chronic lymphocytic leukemia: It was shown that glycoengineered antibodies against CD20 (Obinutuzumab) induce CLL cells phagocytosis by neutrophils, which was accompanied by the increase of CD11b and reduction of CD62L expression [81].